Latest

May 11, 2023, 17:00 ET Cipher Pharmaceuticals Reports First Quarter Results, Highlighted by Record Cash Per Share and Strong Financial Flexibility

(All figures are presented in U.S. dollars) Cash on hand grew by $4.6 million to $33.4 million EPS increased 25% year-over-year to $0.10 Adjusted EBITDA1 of $3.2 million was higher than Q1 2022 and...

May 04, 2023, 17:00 ET Cipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference Call

MISSISSAUGA, ON, May 4, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the first quarter of 2023 on...

Mar 16, 2023, 17:00 ET Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

(All figures are in U.S. dollars) Product revenue increased 9% to $12.5 million in 2022 EBITDA of $12.0 million, relatively flat YoY Cash at December 31, 2022 was $28.8 million (CDN$39 million) or $1....

Mar 10, 2023, 17:30 ET Cipher Pharmaceuticals Schedules Q4 2022 Earnings Release and Conference Call

MISSISSAUGA, ON, March 10, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the three and twelve months...

Mar 01, 2023, 07:00 ET Cipher Pharmaceuticals Announces Closing of New US$35 Million Credit Facility

MISSISSAUGA, ON, March 1, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced completion and closing of a new credit facility (the "Credit Facility") with...

Nov 10, 2022, 18:30 ET Cipher Pharmaceuticals Reports Strong Third Quarter Results, Highlighted by USD$1.09 in Cash Per Share

(All figures are presented in U.S. dollars) EPS increased YoY by $0.08 to $0.11 in the third quarter; Strengthened balance sheet and demonstrated continued positive cash flow, ending Q3 with $27.5...

Oct 26, 2022, 07:00 ET CIPHER PHARMACEUTICALS SCHEDULES Q3 2022 EARNINGS RELEASE AND CONFERENCE CALL

OAKVILLE, ON, Oct. 26, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2022 financial results on Thursday, November 10,...

Sep 19, 2022, 17:00 ET Cipher Pharmaceuticals Announces Normal Course Issuer Bid

MISSISSAUGA, ON, Sept. 19, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted,...

Aug 11, 2022, 17:45 ET Cipher Pharmaceuticals Strengthens Leadership Team with Appointment of New CFO

Experienced finance executive Bryan Jacobs, CPA, CA to join the Company as CFO, effective August 15, 2022. OAKVILLE, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the ...

Aug 11, 2022, 17:01 ET Cipher Pharmaceuticals Reports Second Quarter 2022 Financial Results

(All figures are in U.S. dollars) Drove 7% increase in product revenue to $3.5 million Generated $3.6 million in Adjusted EBITDA Total operating expenses declined 5% to $2.2 million Strong balance...

Aug 05, 2022, 07:00 ET Cipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference Call

MISSISSAUGA, ON, Aug. 5, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q2 2022 financial results on Thursday, August 11,...

Jun 22, 2022, 17:01 ET Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John Mull

MISSISSAUGA, ON, June 22, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and ...

May 12, 2022, 17:00 ET Cipher Pharmaceuticals Reports Strong First Quarter 2022 Financial Results

(All figures are in U.S. dollars) Drove 60% increase in EPS to $0.08 Demonstrated a focus on execution as EBITDA increased 38% to $3.1 million Total operating expenses declined 25% to $2.5 million...

May 09, 2022, 07:00 ET Cipher Pharmaceuticals Schedules Q1 2022 Earnings Release and Conference Call

OAKVILLE, ON, May 9, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q1 2022 financial results on Thursday, May 12, 2022 after ...

Mar 22, 2022, 17:00 ET Cipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 Study

MISSISSAUGA, ON, March 22, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has...

Mar 17, 2022, 17:00 ET Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Demonstrated growth in FY 2021 as EBITDA increased 46% to $11.8 million Disciplined cost structure led to an 18% reduction in SG&A 81% increase in EPS to $0.29 in FY2021 Strengthened cash flow from...

Mar 11, 2022, 17:00 ET Cipher Pharmaceuticals Schedules Q4 2021 Earnings Release and Conference Call

MISSISSAUGA, ON, March 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and...

Mar 10, 2022, 07:00 ET Cipher Pharmaceuticals Announces Extension of Distribution and Supply Agreement with Sun Pharmaceutical Industries Inc.

Royalty agreement granting Sun Pharmaceutical Industries Inc. exclusive right to market, sell and distribute Absorica, Absorica AG and Absorica LD in the U.S. extended through December 31, 2026...

Nov 11, 2021, 17:01 ET Cipher Announces Third Quarter and Year-to-Date 2021 Financial Results

Revenue for nine months ended September 30, 2021increases 4.1% to $16.1 million Adjusted EBITDA1 for nine months ended September 30, 2021 increases to $9.8 million Basic EPS for the nine months ended ...

Nov 03, 2021, 17:01 ET Cipher Pharmaceuticals Schedules Q3 2021 Earnings Release and Conference Call

OAKVILLE, ON, Nov. 3, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2021 financial results on Thursday, November 11, 2021....

Sep 08, 2021, 07:30 ET Cipher Pharmaceuticals Announces Renewal of Normal Course Issuer Bid

OAKVILLE, ON, Sept. 8, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted,...

Aug 12, 2021, 17:00 ET Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica

Revenue increases 30% to $6.1 million, Adjusted EBITDA2 increases 40% to $4.1 million EPS increases 450% to $0.11 (CDN$0.141) Epuris revenue grows 63%, Absorica revenue grows 25% All figures in U.S....

Aug 09, 2021, 07:30 ET Cipher Pharmaceuticals Schedules Q2 2021 Earnings Release and Conference Call

OAKVILLE, ON, Aug. 9, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2021 financial results on Thursday, August 12, 2021. The...

Jun 23, 2021, 17:30 ET Cipher Pharmaceuticals Reports Voting Results From Annual Meeting of Shareholders

OAKVILLE, ON, June 23, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced the voting results for the election of directors at its Annual Meeting of...

May 13, 2021, 17:00 ET Cipher Pharmaceuticals Reports First Quarter 2021 Financial Results

Generates Adjusted EBITDA of $3.6 million and EPS of $0.05 (CDN$0.61) Excluding legal provision EPS was $0.10 (CDN$0.12) OAKVILLE, ON, May 13, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)...